Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2018 Results Conference Call March 5, 2019 5:00 PM ET Company Participants Scott Wolchko - President and CEO Dr. Dan Shoemaker - Chief Scientific Officer Conference Call Participants Ted Tenthoff - Piper Jaffary Kripa Devarakonda - Citi Yanan Zhu - Wells Fargo Biren Amin - Jefferies Matt Biegler - Oppenheimer Reni Benjamin - Raymond James Operator Welcome to the Fate Therapeutics Fourth Quarter 2018 Financial Results Conference Call. At this time, all participants ar ...

Table of Contents Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ or No ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commissio ...